resveratrol has been researched along with gefitinib in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 4 (44.44) | 2.80 |
| Authors | Studies |
|---|---|
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Grubbs, CJ; Juliana, MM; Lubet, RA; Steele, VE | 1 |
| Castillo-Pichardo, L; Dharmawardhane, SF | 1 |
| Chen, H; Gao, X; He, W; Li, B; Mei, C; Xu, R; Zhu, Y | 1 |
| Carbone, ML; Lulli, D; Passarelli, F; Pastore, S | 1 |
| Dyszkiewicz-Konwinska, M; Jodynis-Liebert, J; Jozkowiak, M; Kaczmarek, M; Kranc, W; Piotrowska-Kempisty, H; Ramlau, P; Spaczynska, J; Wierzchowski, M | 1 |
| Dong, H; Guo, L; Yu, J; Zhai, L; Zhang, G; Zhang, Z | 1 |
| Gong, P; Jiang, Y; Li, H; Wu, Y; Zhang, J; Zheng, P; Zhou, Y | 1 |
| Ghazwani, M; Gowda, DV; Gurupadayya, BM; Hani, U; Hemanth Vikram, PR; Osmani, RAM; Sathishbabu, P; Shakeela, C | 1 |
9 other study(ies) available for resveratrol and gefitinib
| Article | Year |
|---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Screening agents for preventive efficacy in a bladder cancer model: study design, end points, and gefitinib and naproxen efficacy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Cyclooxygenase Inhibitors; Disease Models, Animal; Drug Screening Assays, Antitumor; Female; Gefitinib; Naproxen; Quinazolines; Rats; Rats, Inbred F344; Research Design; Resveratrol; Stilbenes; Urinary Bladder Neoplasms | 2010 |
Grape polyphenols inhibit Akt/mammalian target of rapamycin signaling and potentiate the effects of gefitinib in breast cancer.
Topics: Adenylate Kinase; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Caspase 3; Catechin; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation; Humans; Mice; Mice, SCID; Polyphenols; Proto-Oncogene Proteins c-akt; Quercetin; Quinazolines; Resveratrol; Signal Transduction; Sirolimus; Stilbenes; TOR Serine-Threonine Kinases; Vitis; Xenograft Model Antitumor Assays | 2012 |
Resveratrol overcomes gefitinib resistance by increasing the intracellular gefitinib concentration and triggering apoptosis, autophagy and senescence in PC9/G NSCLC cells.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Cytochrome P-450 CYP1A1; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Quinazolines; Resveratrol; Stilbenes | 2015 |
Topical Plant Polyphenols Prevent Type I Interferon Signaling in the Skin and Suppress Contact Hypersensitivity.
Topics: Administration, Topical; Animals; Cells, Cultured; Cetuximab; Chemokine CXCL10; Dermatitis, Allergic Contact; Disease Models, Animal; Gefitinib; Humans; Interferon Regulatory Factor-1; Interferon Type I; Keratinocytes; Mice; Neoplasms; Phosphorylation; Plant Extracts; Polyphenols; Quercetin; Resveratrol; Signal Transduction; STAT1 Transcription Factor | 2018 |
Individual and Combined Treatments with Methylated Resveratrol Analogue DMU-214 and Gefitinib Inhibit Tongue Cancer Cells Growth via Apoptosis Induction and EGFR Inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Cycle; Cell Proliferation; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Resveratrol; Tongue Neoplasms; Tumor Cells, Cultured | 2021 |
Gefitinib-resveratrol Cocrystal with Optimized Performance in Dissolution and Stability.
Topics: Calorimetry, Differential Scanning; Crystallization; Gefitinib; Powder Diffraction; Resveratrol; Solubility; X-Ray Diffraction | 2022 |
Theoretical Study on the Aggregation and Adsorption Behaviors of Anticancer Drug Molecules on Graphene/Graphene Oxide Surface.
Topics: Adsorption; Anastrozole; Antineoplastic Agents; Camptothecin; Gefitinib; Graphite; Molecular Dynamics Simulation; Resveratrol | 2022 |
A novel RP-HPLC method development and validation for simultaneous quantification of gefitinib and resveratrol in polymeric hybrid lipid nanoparticles and glioma cells.
Topics: Chromatography, High Pressure Liquid; Gefitinib; Glioma; Humans; Polymers; Resveratrol | 2022 |